<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255785</url>
  </required_header>
  <id_info>
    <org_study_id>GCF-040</org_study_id>
    <nct_id>NCT03255785</nct_id>
  </id_info>
  <brief_title>Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One iStent and One iStent Supra</brief_title>
  <official_title>A Prospective Evaluation of Mild to Moderate Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glaukos Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glaukos Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open Angle Glaucoma Subjects with Cataract treated with Cataract Surgery plus one trabecular
      micro-bypass stent and one suprachoroidal stent
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>iStent and iStent Supra</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>IOP outcome masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>20% IOP reduction from baseline</measure>
    <time_frame>Month 12</time_frame>
    <description>IOP measured via Goldmann tonometry in mm Hg and compared to baseline IOP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP less than or equal to 18 mm Hg</measure>
    <time_frame>Month 12</time_frame>
    <description>IOP measured via Goldmann tonometry in mm Hg</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>G1 plus G3 with phaco</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cataract surgery via phacoemulsification followed by implantation of one iStent and one iStent Supra</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cataract surgery plus one iStent and one iStent Supra implanted</intervention_name>
    <description>Cataract surgery via phacoemulsfication plus one iStent and one iStent supra</description>
    <arm_group_label>G1 plus G3 with phaco</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinically significant cataract requiring surgery Primary open-angle or
             pseudoexfoliative glaucoma Visual field defects no worse than -12dB Subject on two
             ocular hypotensive medications at screening Medicated IOP at screening between 18 and
             30 mm Hg Normal iridocorneal anatomy Absence of peripheral anterior synechiae

        Exclusion Criteria:

          -  Monocular subjects or those with wore than 20/200 vision in fellow eye Prior stent
             implantation, incision glaucoma surgery, or laser trabeculoplasty in study eye
             Traumatic, uveitic, or neovascular glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeff Wells, PharmD</last_name>
    <phone>949-482-0042</phone>
    <email>jwells@glaukos.com</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

